Press Releases

Date Title and Summary
Toggle Summary Kezar Life Sciences Announces Presentations of Four Abstracts at the 2019 ACR/ARP Annual Meeting
SOUTH SAN FRANCISCO, Calif. , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced four poster presentations
Toggle Summary Kezar Life Sciences to Present at the 2019 Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Sept. 27, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that John Fowler , Chief
Toggle Summary Kezar Life Sciences Announces Presentations at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that members of the senior
Toggle Summary Kezar Life Sciences Announces Presentations at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that members of the senior
Toggle Summary Kezar Life Sciences Reports Second Quarter 2019 Financial Results and Provides Business Update
Promising data reported from the Phase 1b portion of MISSION, a first-in-patient study of KZR-616; Phase 2 portion of MISSION in LN patients has been initiated Phase 2 PRESIDIO and MARINA trials have been initiated evaluating KZR-616 in DM, PM, AIHA, and ITP patients Nomination of first oncology
Toggle Summary Kezar Life Sciences Announces Promising Data from First in Patient Study of KZR-616 at EULAR 2019 Annual Meeting
Repeat dosing of KZR-616 demonstrates tolerability and broad and consistent evidence of efficacy across multiple measures of disease activity Patients receiving KZR-616 have not experienced the hematologic and constitutional toxicities seen with approved nonselective proteasome inhibitors Phase 2
Toggle Summary Kezar Life Sciences to Host Conference Call and Webcast at the EULAR 2019 Annual Meeting to Discuss Results of First in Patient Study with KZR-616
Conference call and webcast scheduled for Thursday, June 13, 2019 at 4:05 p.m. EDT SOUTH SAN FRANCISCO, Calif. , June 10, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat
Toggle Summary Kezar Life Sciences Announces Acceptance of Abstract for Presentation of First in Patient Study with KZR-616 at EULAR 2019 Annual Meeting
Abstract highlights preliminary results from the first two cohorts of the Phase 1b portion of the MISSION Trial in patients with systemic lupus erythematosus (SLE) Detailed poster with additional results will be presented during EULAR 2019 in Madrid SOUTH SAN FRANCISCO, Calif.
Toggle Summary Kezar Life Sciences Announces Presentations at Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. , May 14, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that members of the senior
Toggle Summary Kezar Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update
Phase 1b systemic lupus erythematosus (SLE) top-line data release and Phase 2 lupus nephritis (LN) initiation on track in Q2 2019 Site selection underway for Phase 2 trial of KZR-616 for the treatment of dermatomyositis (DM) and polymyositis (PM)—trial on track to begin in 2H 2019 FDA accepts